FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology, specifically to novel hetero-multimeric proteins obtained from modified ubiquitin, and can be used in medicine to treat or diagnose diseases associated with hyperprodution of the extradomain B of fibronectin (ED-B). The protein includes two monomeric ubiquitin links which are differently modified through substitutions of at least 6 amino acids in positions 4, 6, 8, 62, 63, 64, 65 and 66 of SEQ ID NO: 1. In the first monomer link the substitutions include: F4W, K6(H, W or F), Q62N, E64(K, R or H), S65(L, F or W), T66(S or P), and in the second monomer link: K6(T, N, S or Q), L8(Q, T, N or S), Q62(W or F), K63(S, T, N or Q), E64(N, S, T or Q), S65(F or W), T66(E or D).
EFFECT: invention enables to obtain a modified heterodimeric ubiquitin protein, capable of binding with ED-B with high affinity.
28 cl, 18 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF IDENTIFYING HETEROMULTIMERIC MODIFIED UBIQUITIN PROTEINS POSSESSING ABILITY TO BIND WITH LIGANDS | 2010 |
|
RU2553333C2 |
| SPECIFIC AND HIGH-AFFINITY BINDING PROTEINS CONTAINING MODIFIED SH3-DOMAINS OF Fyn KINASE | 2007 |
|
RU2478707C2 |
| NOVEL IL-17-BINDING COMPOUNDS AND THEIR MEDICINAL APPLICATION | 2010 |
|
RU2550272C2 |
| TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS | 2011 |
|
RU2628699C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| RECEPTOR OF FIBRONECTIN ED-DOMEN | 2001 |
|
RU2280254C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY TO CERTAIN TARGET | 2010 |
|
RU2564125C2 |
| ANTAGONISTS AND METHOD OF USING SAID ANTAGONISTS | 2005 |
|
RU2401842C2 |
| ANTIBODIES | 2018 |
|
RU2798399C2 |
| ANTIBODIES TO POLYUBIQUITIN AND METHODS OF APPLICATION THEREOF | 2011 |
|
RU2603093C2 |
